HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
Sungchul Lee, CEO of LSKB, will export Targeted anti-cancer therapies to multinational company
“Will surprise Bio Industry with Speedy competency”
Sungchul Kim, CEO of LSKB, added “We will properly dig new drug candidates with much potent.”
LSKB, a Bio firm running in the US, is a subsidiary of a KOSDAQ listed company named HLB’s..
Not like existing pharmaceutical companies, he has set plans for LSKB as a development oriented one, selecting commercially much potent new drug candidates to have clinical experiment procedures.
That means, he would focus on development of potent new drug candidates, reducing time for researching. Targeted anti-cancer therapies is one of its challenge.
Now, after completing its clinical phase II, it is under pursuant of phase III in the US. Apatinib is already being sold in China..
Chinese pharmaceutical company named HungLoui, who bought all Chinese distributorship, received a marketing authorization on the terminal gastric cancer therapeutics
He said, “it has higher possibility of success during the development since it has proved competency in Chinese market”.
Kim is expecting to export Apatinib’s technology to global pharmaceutical companies while proceeding its clinical phase III. And he will continuously expand Apatinib’s applications, preparing for clinical experiments for liver cancer therapies. He has begun commercializing next new drug candidates, as well.
The sales authority of HCI-1401’s, bought from Huntsman Cancer Center at Univ. of Utah last month is the case. It is one of the new drug candidates applicable to be developed as blood cancer and immune disease treatment.
Eventually, it’s his resolution, listing on NASDAQ for strengthening LSKB as an US bio firm based in Korea. “Though it may take times, I will take step by step forward, developing and commercializing good new drug candidates”, he says.